PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

Marcelo V. Negrao, Vincent Lam, Alexandre Reuben, Maria Laura Rubin, Lara Lacerda Landry, Emily B. Roarty, Waree Rinsurongkawong, Jeff Lewis, Jack A. Roth, Stephen G. Swisher, Don L. Gibbons, Ignacio I. Wistuba, Vassiliki Papadimitrakopoulou, Bonnie S. Glisson, George R. Blumenschein, J. Jack Lee, John V. Heymach, Jianjun Zhang

Research output: Contribution to journalArticle

Abstract

Introduction: Immune checkpoint blockade (ICB) has revolutionized the treatment of NSCLC, but only approximately 15% of patients achieve durable benefit. Understanding mechanisms of resistance to ICB is pivotal in developing more effective treatment strategies. Recent studies showed that human leukocyte antigen (HLA) class I heterozygosity might be important in mediating benefit from ICB. We aimed to investigate the impact of HLA class I genotype on outcomes of patients with NSCLC treated with ICB. Methods: We collected HLA typing, genomic, and clinical data from patients with advanced NSCLC treated with ICB at M. D. Anderson Cancer Center. We compared HLA class I–heterozygous and HLA class I–homozygous patients for progression-free survival (PFS) and overall survival (OS). HLA I supertype/alleles were also analyzed. To validate our findings, we also analyzed two previously published independent cohorts of patients with NSCLC (the CheckMate-012 and Chowell cohorts). Results: No significant correlations were observed for HLA class I zygosity and PFS or OS in the M. D. Anderson Cancer Center (n = 200), CheckMate-012 (n = 75), or Chowell (n = 371) cohorts. No HLA class I supertype/allele was consistently shown to be correlated with PFS or OS. Predictors of worse outcome across the three cohorts included presence of targetable driver mutation, serine/threonine kinase 11 gene (STK11) mutation, negative programmed death ligand 1 expression, and low tumor mutational burden. Conclusions: HLA class I genotype is not correlated with survival in advanced NSCLC treated with ICB. This suggests that the impact of HLA class I diversity may be disease specific and that tumor genomic and immune markers are more impactful in predicting benefit from ICB in NSCLC.

Original languageEnglish (US)
Pages (from-to)1021-1031
Number of pages11
JournalJournal of Thoracic Oncology
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2019
Externally publishedYes

Fingerprint

Neoplasm Genes
HLA Antigens
Tumor Burden
Non-Small Cell Lung Carcinoma
Genotype
Mutation
Disease-Free Survival
Survival
Alleles
Protein-Serine-Threonine Kinases
Tumor Biomarkers
Neoplasms
Biomarkers
Ligands

Keywords

  • HLA class I
  • Immunotherapy
  • Lung cancer
  • PD-L1
  • Tumor mutational burden

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer. / Negrao, Marcelo V.; Lam, Vincent; Reuben, Alexandre; Rubin, Maria Laura; Landry, Lara Lacerda; Roarty, Emily B.; Rinsurongkawong, Waree; Lewis, Jeff; Roth, Jack A.; Swisher, Stephen G.; Gibbons, Don L.; Wistuba, Ignacio I.; Papadimitrakopoulou, Vassiliki; Glisson, Bonnie S.; Blumenschein, George R.; Lee, J. Jack; Heymach, John V.; Zhang, Jianjun.

In: Journal of Thoracic Oncology, Vol. 14, No. 6, 01.06.2019, p. 1021-1031.

Research output: Contribution to journalArticle

Negrao, MV, Lam, V, Reuben, A, Rubin, ML, Landry, LL, Roarty, EB, Rinsurongkawong, W, Lewis, J, Roth, JA, Swisher, SG, Gibbons, DL, Wistuba, II, Papadimitrakopoulou, V, Glisson, BS, Blumenschein, GR, Lee, JJ, Heymach, JV & Zhang, J 2019, 'PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer', Journal of Thoracic Oncology, vol. 14, no. 6, pp. 1021-1031. https://doi.org/10.1016/j.jtho.2019.02.008
Negrao, Marcelo V. ; Lam, Vincent ; Reuben, Alexandre ; Rubin, Maria Laura ; Landry, Lara Lacerda ; Roarty, Emily B. ; Rinsurongkawong, Waree ; Lewis, Jeff ; Roth, Jack A. ; Swisher, Stephen G. ; Gibbons, Don L. ; Wistuba, Ignacio I. ; Papadimitrakopoulou, Vassiliki ; Glisson, Bonnie S. ; Blumenschein, George R. ; Lee, J. Jack ; Heymach, John V. ; Zhang, Jianjun. / PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer. In: Journal of Thoracic Oncology. 2019 ; Vol. 14, No. 6. pp. 1021-1031.
@article{6e60cb8116894ba693e64c91632ddba1,
title = "PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer",
abstract = "Introduction: Immune checkpoint blockade (ICB) has revolutionized the treatment of NSCLC, but only approximately 15{\%} of patients achieve durable benefit. Understanding mechanisms of resistance to ICB is pivotal in developing more effective treatment strategies. Recent studies showed that human leukocyte antigen (HLA) class I heterozygosity might be important in mediating benefit from ICB. We aimed to investigate the impact of HLA class I genotype on outcomes of patients with NSCLC treated with ICB. Methods: We collected HLA typing, genomic, and clinical data from patients with advanced NSCLC treated with ICB at M. D. Anderson Cancer Center. We compared HLA class I–heterozygous and HLA class I–homozygous patients for progression-free survival (PFS) and overall survival (OS). HLA I supertype/alleles were also analyzed. To validate our findings, we also analyzed two previously published independent cohorts of patients with NSCLC (the CheckMate-012 and Chowell cohorts). Results: No significant correlations were observed for HLA class I zygosity and PFS or OS in the M. D. Anderson Cancer Center (n = 200), CheckMate-012 (n = 75), or Chowell (n = 371) cohorts. No HLA class I supertype/allele was consistently shown to be correlated with PFS or OS. Predictors of worse outcome across the three cohorts included presence of targetable driver mutation, serine/threonine kinase 11 gene (STK11) mutation, negative programmed death ligand 1 expression, and low tumor mutational burden. Conclusions: HLA class I genotype is not correlated with survival in advanced NSCLC treated with ICB. This suggests that the impact of HLA class I diversity may be disease specific and that tumor genomic and immune markers are more impactful in predicting benefit from ICB in NSCLC.",
keywords = "HLA class I, Immunotherapy, Lung cancer, PD-L1, Tumor mutational burden",
author = "Negrao, {Marcelo V.} and Vincent Lam and Alexandre Reuben and Rubin, {Maria Laura} and Landry, {Lara Lacerda} and Roarty, {Emily B.} and Waree Rinsurongkawong and Jeff Lewis and Roth, {Jack A.} and Swisher, {Stephen G.} and Gibbons, {Don L.} and Wistuba, {Ignacio I.} and Vassiliki Papadimitrakopoulou and Glisson, {Bonnie S.} and Blumenschein, {George R.} and Lee, {J. Jack} and Heymach, {John V.} and Jianjun Zhang",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.jtho.2019.02.008",
language = "English (US)",
volume = "14",
pages = "1021--1031",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",

}

TY - JOUR

T1 - PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

AU - Negrao, Marcelo V.

AU - Lam, Vincent

AU - Reuben, Alexandre

AU - Rubin, Maria Laura

AU - Landry, Lara Lacerda

AU - Roarty, Emily B.

AU - Rinsurongkawong, Waree

AU - Lewis, Jeff

AU - Roth, Jack A.

AU - Swisher, Stephen G.

AU - Gibbons, Don L.

AU - Wistuba, Ignacio I.

AU - Papadimitrakopoulou, Vassiliki

AU - Glisson, Bonnie S.

AU - Blumenschein, George R.

AU - Lee, J. Jack

AU - Heymach, John V.

AU - Zhang, Jianjun

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Introduction: Immune checkpoint blockade (ICB) has revolutionized the treatment of NSCLC, but only approximately 15% of patients achieve durable benefit. Understanding mechanisms of resistance to ICB is pivotal in developing more effective treatment strategies. Recent studies showed that human leukocyte antigen (HLA) class I heterozygosity might be important in mediating benefit from ICB. We aimed to investigate the impact of HLA class I genotype on outcomes of patients with NSCLC treated with ICB. Methods: We collected HLA typing, genomic, and clinical data from patients with advanced NSCLC treated with ICB at M. D. Anderson Cancer Center. We compared HLA class I–heterozygous and HLA class I–homozygous patients for progression-free survival (PFS) and overall survival (OS). HLA I supertype/alleles were also analyzed. To validate our findings, we also analyzed two previously published independent cohorts of patients with NSCLC (the CheckMate-012 and Chowell cohorts). Results: No significant correlations were observed for HLA class I zygosity and PFS or OS in the M. D. Anderson Cancer Center (n = 200), CheckMate-012 (n = 75), or Chowell (n = 371) cohorts. No HLA class I supertype/allele was consistently shown to be correlated with PFS or OS. Predictors of worse outcome across the three cohorts included presence of targetable driver mutation, serine/threonine kinase 11 gene (STK11) mutation, negative programmed death ligand 1 expression, and low tumor mutational burden. Conclusions: HLA class I genotype is not correlated with survival in advanced NSCLC treated with ICB. This suggests that the impact of HLA class I diversity may be disease specific and that tumor genomic and immune markers are more impactful in predicting benefit from ICB in NSCLC.

AB - Introduction: Immune checkpoint blockade (ICB) has revolutionized the treatment of NSCLC, but only approximately 15% of patients achieve durable benefit. Understanding mechanisms of resistance to ICB is pivotal in developing more effective treatment strategies. Recent studies showed that human leukocyte antigen (HLA) class I heterozygosity might be important in mediating benefit from ICB. We aimed to investigate the impact of HLA class I genotype on outcomes of patients with NSCLC treated with ICB. Methods: We collected HLA typing, genomic, and clinical data from patients with advanced NSCLC treated with ICB at M. D. Anderson Cancer Center. We compared HLA class I–heterozygous and HLA class I–homozygous patients for progression-free survival (PFS) and overall survival (OS). HLA I supertype/alleles were also analyzed. To validate our findings, we also analyzed two previously published independent cohorts of patients with NSCLC (the CheckMate-012 and Chowell cohorts). Results: No significant correlations were observed for HLA class I zygosity and PFS or OS in the M. D. Anderson Cancer Center (n = 200), CheckMate-012 (n = 75), or Chowell (n = 371) cohorts. No HLA class I supertype/allele was consistently shown to be correlated with PFS or OS. Predictors of worse outcome across the three cohorts included presence of targetable driver mutation, serine/threonine kinase 11 gene (STK11) mutation, negative programmed death ligand 1 expression, and low tumor mutational burden. Conclusions: HLA class I genotype is not correlated with survival in advanced NSCLC treated with ICB. This suggests that the impact of HLA class I diversity may be disease specific and that tumor genomic and immune markers are more impactful in predicting benefit from ICB in NSCLC.

KW - HLA class I

KW - Immunotherapy

KW - Lung cancer

KW - PD-L1

KW - Tumor mutational burden

UR - http://www.scopus.com/inward/record.url?scp=85063758592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063758592&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2019.02.008

DO - 10.1016/j.jtho.2019.02.008

M3 - Article

C2 - 30780001

AN - SCOPUS:85063758592

VL - 14

SP - 1021

EP - 1031

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -